Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02415881 · ClinicalTrials.gov registry record · Phase 1
Panitumumab IRDye800 Optical Imaging Study
A Phase 1 study, sponsored by Eben Rosenthal.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT02415881 is a Phase 1 study that has completed, run by Eben Rosenthal. The registered enrollment target is 64 participants.
The verdict
NCT02415881, a Phase 1 study, has completed, sponsored by Eben Rosenthal.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
Phase I trial to evaluate the safety of escalating dose levels of conjugated panitumumab-IRDye800 in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent.
Interventions
- DRUG Panitumumab IRDye 800
- DEVICE da Vinci Firefly
- DEVICE IMAGE1 + ICG Hopkins telescope and/or VITOM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2016-08 |
| Est. Completion | 2021-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02415881
The ClinicalTrials.gov registry entry for NCT02415881 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eben Rosenthal, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Panitumumab IRDye 800 is the first listed.
NCT02415881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02415881 about?
NCT02415881 is a clinical study titled "Panitumumab IRDye800 Optical Imaging Study". Phase I trial to evaluate the safety of escalating dose levels of conjugated panitumumab-IRDye800 in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent.
What is the current status of trial NCT02415881?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2016-08. Estimated completion is 2021-09-21.
What interventions are being tested in trial NCT02415881?
The interventions under investigation include: Panitumumab IRDye 800 (DRUG), da Vinci Firefly (DEVICE), IMAGE1 + ICG Hopkins telescope and/or VITOM (DEVICE).
Who is sponsoring clinical trial NCT02415881?
This trial is sponsored by Eben Rosenthal, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.